Sharlene Gill, MD, MPH, FACP, FRCPC, highlights significant research data on developments in the treatment of GIST and NETs.
Dr Janjigian shares her perspective on HER2-targeted therapy data from the DELIVER, KEYNOTE-061, DESTINY-Gastric01, and RTOG1010 trials.
Dr Mukherji summarizes 3 posters that were presented at the 2020 ESMO World Congress on GI Cancer, which identify gaps in research and can inform future biliary tract cancer trials.
Dr Ramaswamy provides perspective on a phase 2 trial comparing the efficacy of irinotecan administered with or without capecitabine for advanced gallbladder cancer.
Solange Peters, MD, PhD, discusses the motivation behind her Keynote Presentation on women in oncology, which will take place virtually on July 4th at the 2020 ESMO World Congress on GI Cancer.
Dr Grothey tells us what we can look forward to at the 22nd ESMO World Congress on Gastrointestinal Cancer, which is taking place virtually this year.
The President of ESMO discusses what attendees of the annual ESMO World Congress on GI Cancer can expect from the virtual 2020 event.
At ESMO World GI, experts reviewed optimal treatments and best sequencing based on level of evidence for various metastatic GI cancers.
Stay in the know.
OncNet Newsletter